MCID: GST105
MIFTS: 45

Gastroesophageal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastroesophageal Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Adenocarcinoma:

Name: Gastroesophageal Adenocarcinoma 12 15
Gastric and Esophageal Adenocarcinoma 12
Gastro-Esophageal Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0080375

Summaries for Gastroesophageal Adenocarcinoma

Disease Ontology : 12 A gastroesophageal cancer that has material basis in abnormally proliferating cells, derives from epithelial cells, which originate in glandular tissue.

MalaCards based summary : Gastroesophageal Adenocarcinoma, also known as gastric and esophageal adenocarcinoma, is related to gastric cancer and adenocarcinoma. An important gene associated with Gastroesophageal Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Activation of cAMP-Dependent PKA and TGF-Beta Pathway. The drugs leucovorin and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Gastroesophageal Adenocarcinoma

Diseases related to Gastroesophageal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Related Disease Score Top Affiliating Genes
1 gastric cancer 29.2 EGFR ERBB2 GSTM1 MET TYMS
2 adenocarcinoma 10.9
3 breast intraductal proliferative lesion 10.2 EGFR ERBB2
4 progesterone-receptor negative breast cancer 10.2 EGFR ERBB2
5 breast scirrhous carcinoma 10.2 EGFR ERBB2
6 breast squamous cell carcinoma 10.2 EGFR ERBB2
7 microglandular adenosis 10.2 EGFR ERBB2
8 inflammatory breast carcinoma 10.2 EGFR ERBB2
9 doxorubicin induced cardiomyopathy 10.2 EGFR MET
10 luminal breast carcinoma 10.2 EGFR ERBB2
11 acneiform dermatitis 10.2 EGFR ERBB2
12 lipid-rich carcinoma 10.2 EGFR ERBB2
13 mucinous lung adenocarcinoma 10.2 EGFR ERBB2
14 hidradenocarcinoma 10.2 EGFR ERBB2
15 familial renal papillary carcinoma 10.2 EGFR MET
16 mammary paget's disease 10.2 EGFR ERBB2
17 primary peritoneal carcinoma 10.2 EGFR ERBB2
18 adenosquamous lung carcinoma 10.1 EGFR ERBB2
19 pre-malignant neoplasm 10.1 EGFR ERBB2
20 spinal chordoma 10.1 EGFR MET
21 cardia cancer 10.1 GSTM1 TYMS
22 exanthem 10.1 EGFR ERBB2
23 papillary adenocarcinoma 10.1 ERBB2 MST1R
24 in situ carcinoma 10.1 EGFR ERBB2
25 breast carcinoma in situ 10.0 EGFR ERBB2 MET
26 stomach disease 10.0 EGFR ERBB2 MET
27 breast ductal carcinoma 10.0 EGFR ERBB2 MET
28 laryngeal disease 10.0 EGFR GSTM1
29 body mass index quantitative trait locus 1 10.0
30 esophageal disease 10.0 EGFR ERBB2
31 cholangiocarcinoma 10.0 EGFR ERBB2 MET
32 glioblastoma multiforme 10.0 EGFR ERBB2 MET
33 helicobacter pylori infection 10.0 EGFR MET
34 oral cavity cancer 9.9 EGFR ERBB2 GSTM1
35 adamantinoma of long bones 9.9 EGFR ERBB2 GSTM1
36 sclerosing cholangitis, neonatal 9.8
37 hemolytic anemia 9.8
38 patulous eustachian tube 9.8
39 pharynx cancer 9.8 EGFR GSTM1
40 estrogen-receptor positive breast cancer 9.8 EGFR ERBB2
41 glioma 9.8 EGFR ERBB2 MET
42 gastrointestinal system cancer 9.8 EGFR ERBB2 MET TYMS
43 gallbladder adenocarcinoma 9.8 EGFR ERBB2 SRC
44 respiratory system cancer 9.7 EGFR ERBB2 GSTM1 MET
45 squamous cell carcinoma, head and neck 9.7 EGFR ERBB2 GSTM1 MET
46 esophageal cancer 9.7 EGFR ERBB2 GSTM1 TYMS
47 nasopharyngeal carcinoma 9.6 EGFR GSTM1 MST1R
48 pancreas adenocarcinoma 9.6 EGFR ERBB2 MET SRC
49 lung cancer susceptibility 3 9.5 EGFR ERBB2 MET SRC
50 glioblastoma 9.5 EGFR ERBB2 MET SRC

Graphical network of the top 20 diseases related to Gastroesophageal Adenocarcinoma:



Diseases related to Gastroesophageal Adenocarcinoma

Symptoms & Phenotypes for Gastroesophageal Adenocarcinoma

GenomeRNAi Phenotypes related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

27 (show all 35)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.89 MST1R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.89 MET
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.89 MST1R
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.89 MET
5 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.89 EGFR
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.89 EGFR
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.89 MST1R
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.89 MST1R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.89 MST1R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.89 MST1R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.89 ERBB2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.89 ERBB2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.89 MET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.89 ERBB2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.89 MST1R
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.89 MST1R
17 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.89 MET
18 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.89 MET
19 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.89 EGFR
20 Increased shRNA abundance (Z-score > 2) GR00366-A-201 9.89 MET
21 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.89 ERBB2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.89 EGFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.89 EGFR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.89 ERBB2 MST1R
25 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.89 MET
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.89 EGFR MST1R
27 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.89 MST1R
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.89 ERBB2 MET
29 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.89 MET
30 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.89 MST1R
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.89 EGFR ERBB2 MET MST1R
32 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.56 EGFR ERBB2 GSTM1 MST1R
33 Decreased viability with paclitaxel GR00179-A-1 9.46 EGFR ERBB2 SRC
34 Decreased viability with paclitaxel GR00179-A-3 9.46 EGFR
35 Increased cell viability after pRB stimulation GR00230-A-1 9.13 EGFR ERBB2 MET

Drugs & Therapeutics for Gastroesophageal Adenocarcinoma

Drugs for Gastroesophageal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
2
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 4,Phase 2 100286-90-6, 97682-44-5 60838
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
7
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 7440-70-2 271
8 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
9 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
10 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
12 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Folate Phase 4,Phase 3,Phase 2,Phase 1
16 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
17 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
18 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
19 Vitamin B9 Phase 4,Phase 3,Phase 2,Phase 1
20 Nutrients Phase 4,Phase 3,Phase 2,Phase 1
21 Hormones Phase 4,Phase 3,Phase 1,Phase 2
22 Calcium, Dietary Phase 4,Phase 3,Phase 1,Phase 2
23 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 topoisomerase I inhibitors Phase 4,Phase 2
25
Epirubicin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
26
Cisplatin Approved Phase 3,Phase 2,Early Phase 1 15663-27-1 2767 441203 84093
27
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124
28
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
29
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 1 154361-50-9 60953
30
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 1 33069-62-4 36314
31 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Early Phase 1
33 Antimitotic Agents Phase 2, Phase 3,Phase 1
34 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 1
35 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 1
36
Panitumumab Approved, Investigational Phase 2,Phase 1 339177-26-3 50070211
37
Bevacizumab Approved, Investigational Phase 2 216974-75-3
38
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 46835353 5284616 6436030
39
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
40
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
41
Ramucirumab Approved, Investigational Phase 2,Early Phase 1 947687-13-0
42
nivolumab Approved Phase 2,Phase 1 946414-94-4
43
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
44
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
45
afatinib Approved Phase 2 850140-72-6, 439081-18-2 10184653
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
48
Floxuridine Approved Phase 2 50-91-9 5790
49
Rilotumumab Investigational Phase 2 872514-65-3
50 Antibodies Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
2 Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial Unknown status NCT02780921 Phase 3
3 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer Completed NCT00052910 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
4 Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma Recruiting NCT01404156 Phase 2, Phase 3 (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel
5 MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma Unknown status NCT01443065 Phase 2 Oxaliplatin;Folinic Acid;5-fluoro-uracil;panitumumab;AMG102
6 Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma Completed NCT01757171 Phase 2 Cabazitaxel
7 Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma Completed NCT00390416 Phase 2 Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
8 Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma Completed NCT00816543 Phase 2 DOCETAXEL;S-1;OXALIPLATIN
9 Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma Completed NCT01932580 Phase 2 FLOT (5-fluorouracil, oxaliplatin, docetaxel)
10 Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer Completed NCT01231399 Phase 1, Phase 2 fluorouracil;leucovorin calcium;oxaliplatin;everolimus
11 Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer Completed NCT00073502 Phase 2 OSI-7904L
12 Avastin and Tarceva for Upper Gastrointestinal Cancers Completed NCT00350753 Phase 2 Erlotinib and bevacizumab
13 Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies Completed NCT01045421 Phase 1, Phase 2 MLN8237 (Alisertib)
14 A Safety and Efficacy Study of ZW25 Plus Combination Chemotherapy in HER2-expressing Gastroesophageal Adenocarcinoma Recruiting NCT03929666 Phase 2 ZW25;Capecitabine;Cisplatin;Fluorouracil;Leucovorin;Oxaliplatin
15 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Recruiting NCT02213289 Phase 2
16 FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma Recruiting NCT03528876 Phase 2 FOLFOX and FOLFIRI
17 A Study of a Personalized Neoantigen Cancer Vaccine Recruiting NCT03639714 Phase 1, Phase 2
18 Herzuma-capecitabine/Cisplatin for Gastric Cancer Recruiting NCT03588533 Phase 2 Trastuzumab;Capecitabine;Cisplatin
19 Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer Recruiting NCT02317991 Phase 2 nab-paclitaxel
20 Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Recruiting NCT03783936 Phase 2 Oxaliplatin;Leucovorin;5 fluorouracil;Trastuzumab;Avelumab
21 Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer Active, not recruiting NCT01743365 Phase 2 Cisplatin-5FU-Afatinib
22 Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma Terminated NCT01182610 Phase 2 Panitumumab;Paclitaxel;Carboplatin;5FU
23 Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma Terminated NCT00667420 Phase 1, Phase 2 panitumumab, epirubicin, oxaliplatin, xeloda
24 A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers Terminated NCT00177255 Phase 2 Docetaxel;Capecitabine
25 Chemotherapy for Patients With Gastroesophageal Cancers Who Have Progressed After One Prior Chemo Regimen Terminated NCT01365130 Phase 2 jevtana
26 First Line Chemotherapy for Advanced Cancer Terminated NCT01980810 Phase 2 albumin-bounded paclitaxel;S-1
27 Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers Terminated NCT00848783 Phase 2 Irinotecan;Cisplatin;Floxuridine;Capecitabine
28 C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Withdrawn NCT02344810 Phase 1, Phase 2 c-Met inhibitor AMG 337;oxaliplatin;leucovorin calcium;fluorouracil
29 Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer Completed NCT00909025 Phase 1 Claudiximab
30 Study of BAY1834942 in Patients With Solid Tumors Recruiting NCT03596372 Phase 1 BAY1834942;BAY1834942 + Pembrolizumab
31 LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma Active, not recruiting NCT02138929 Phase 1 Everolimus;LDE 225
32 MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma Terminated NCT02551055 Phase 1 MLN1117;TAK-659;Alisertib;Paclitaxel;Docetaxel
33 Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT00215514 Early Phase 1 Epirubicin;Cisplatin;5-Fluorouracil (5-FU)
34 Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer Recruiting NCT03784326 Early Phase 1 Atezolizumab;Fluorouracil;Oxaliplatin
35 A Study of Personalized Neoantigen Cancer Vaccines Recruiting NCT03794128
36 A Study of Pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma Active, not recruiting NCT03395847 Early Phase 1 Pembrolizumab
37 Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy Not yet recruiting NCT03613142 Not Applicable

Search NIH Clinical Center for Gastroesophageal Adenocarcinoma

Genetic Tests for Gastroesophageal Adenocarcinoma

Anatomical Context for Gastroesophageal Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Adenocarcinoma:

42
Breast, Lung, Bone, Testes, Brain, Skeletal Muscle, Bone Marrow

Publications for Gastroesophageal Adenocarcinoma

Articles related to Gastroesophageal Adenocarcinoma:

(show top 50) (show all 118)
# Title Authors Year
1
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma. ( 31101074 )
2019
2
Towards precision oncology for anti-HER2 blockade in gastroesophageal adenocarcinoma. ( 31046106 )
2019
3
Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. ( 30893708 )
2019
4
Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology. ( 30851910 )
2019
5
High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma. ( 30706229 )
2019
6
Treatment of Patients with Advanced Gastroesophageal Adenocarcinoma: Does Age Matter? ( 30680677 )
2019
7
Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. ( 30419350 )
2018
8
Prevalence of False-Negative Results of Intraoperative Consultation on Surgical Margins During Resection of Gastric and Gastroesophageal Adenocarcinoma. ( 30422226 )
2018
9
Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. ( 30355278 )
2018
10
Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in epidermal growth factor receptor-2-negative, mesenchymal-epithelial transition-positive gastroesophageal adenocarcinoma: is it a real failure? ( 30363693 )
2018
11
Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response. ( 29961919 )
2018
12
Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma. ( 29884598 )
2018
13
Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. ( 29901103 )
2018
14
EGFR Amplification as a Target in Gastroesophageal Adenocarcinoma: Do Anti-EGFR Therapies Deserve a Second Chance? ( 29858225 )
2018
15
Customization of therapy for gastroesophageal adenocarcinoma patients. ( 29756119 )
2018
16
Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. ( 29771279 )
2018
17
Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study. ( 28913947 )
2018
18
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. ( 28978556 )
2018
19
Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance. ( 29318901 )
2018
20
Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. ( 29429124 )
2018
21
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. ( 29449271 )
2018
22
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma. ( 29674442 )
2018
23
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma. ( 25144267 )
2017
24
Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma. ( 27425578 )
2017
25
PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. ( 27517839 )
2017
26
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. ( 27530622 )
2017
27
PET-CT Post-Hepatic Radiation Changes in Gastroesophageal Adenocarcinoma. ( 27749425 )
2017
28
Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. ( 27770339 )
2017
29
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. ( 27811012 )
2017
30
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. ( 27907277 )
2017
31
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. ( 27918764 )
2017
32
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. ( 27926778 )
2017
33
It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. ( 28129519 )
2017
34
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. ( 28129524 )
2017
35
The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. ( 28306358 )
2017
36
Current status of ramucirumab in gastroesophageal adenocarcinoma. ( 28436242 )
2017
37
Optimal radial force and size for palliation in gastroesophageal adenocarcinoma: a comparative analysis of current stent technology. ( 28444492 )
2017
38
Update on Gastroesophageal Adenocarcinoma Targeted Therapies. ( 28501091 )
2017
39
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). ( 28551325 )
2017
40
Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. ( 28810883 )
2017
41
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. ( 27836862 )
2017
42
Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma. ( 25758761 )
2016
43
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. ( 26628478 )
2016
44
The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality. ( 26792144 )
2016
45
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( 27093189 )
2016
46
Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. ( 27120436 )
2016
47
Neoadjuvant therapy for gastroesophageal adenocarcinoma. ( 27298768 )
2016
48
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. ( 27623185 )
2016
49
Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma. ( 27726290 )
2016
50
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. ( 27841667 )
2016

Variations for Gastroesophageal Adenocarcinoma

Expression for Gastroesophageal Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Adenocarcinoma.

Pathways for Gastroesophageal Adenocarcinoma

Pathways related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 EGFR ERBB2 MET MST1R SRC
2
Show member pathways
13.33 EGFR ERBB2 MET MST1R SRC
3
Show member pathways
13.21 EGFR ERBB2 MET MST1R SRC
4
Show member pathways
13.11 EGFR ERBB2 MET MST1R SRC
5
Show member pathways
13.06 EGFR ERBB2 MET MST1R SRC
6
Show member pathways
12.74 EGFR ERBB2 MET MST1R SRC
7
Show member pathways
12.73 EGFR ERBB2 MET SRC
8
Show member pathways
12.72 EGFR ERBB2 MET SRC
9 12.66 EGFR ERBB2 GSTM1 MET
10
Show member pathways
12.57 EGFR ERBB2 GSTM1 MET
11
Show member pathways
12.52 EGFR ERBB2 MET SRC
12
Show member pathways
12.5 EGFR ERBB2 MET SRC
13
Show member pathways
12.43 EGFR ERBB2 SRC
14
Show member pathways
12.39 EGFR ERBB2 MET SRC
15
Show member pathways
12.38 EGFR ERBB2 SRC
16 12.35 EGFR ERBB2 MET
17
Show member pathways
12.34 EGFR ERBB2 MET
18
Show member pathways
12.31 EGFR MET SRC
19
Show member pathways
12.28 EGFR ERBB2 MET
20
Show member pathways
12.17 EGFR ERBB2 SRC
21 12.04 EGFR ERBB2 SRC
22 12.04 EGFR ERBB2 MET SRC
23
Show member pathways
12.02 EGFR ERBB2 MET MST1R SRC
24 11.99 EGFR ERBB2 MET
25
Show member pathways
11.98 EGFR ERBB2 SRC
26
Show member pathways
11.98 EGFR ERBB2 MET SRC
27
Show member pathways
11.96 EGFR ERBB2 SRC
28
Show member pathways
11.86 EGFR ERBB2 SRC
29
Show member pathways
11.71 EGFR MET SRC
30 11.6 EGFR ERBB2 SRC
31 11.56 EGFR ERBB2 SRC
32 11.52 EGFR ERBB2 MET MST1R SRC
33 11.51 EGFR ERBB2 MET
34
Show member pathways
11.45 EGFR ERBB2 SRC
35 11.41 EGFR SRC
36 11.41 EGFR ERBB2 SRC
37 11.39 MST1R SRC
38 11.39 EGFR SRC
39 11.39 EGFR SRC
40 11.39 KLK6 MST1R
41 11.38 MET SRC
42 11.36 EGFR SRC
43 11.31 EGFR ERBB2 MET SRC
44 11.29 MET SRC
45 11.29 EGFR MET
46 11.29 EGFR ERBB2 SRC
47 11.21 EGFR SRC
48
Show member pathways
11.2 EGFR MET SRC
49 11.18 KLK6 SRC
50 11.08 EGFR MET SRC

GO Terms for Gastroesophageal Adenocarcinoma

Cellular components related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.63 EGFR ERBB2 GSTM1 KLK6 SRC TYMS
2 receptor complex GO:0043235 9.26 EGFR ERBB2 MET MST1R
3 basal plasma membrane GO:0009925 8.8 EGFR ERBB2 MET

Biological processes related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.85 EGFR ERBB2 MET MST1R SRC
2 protein phosphorylation GO:0006468 9.83 EGFR ERBB2 MET MST1R SRC
3 cell proliferation GO:0008283 9.81 EGFR ERBB2 MET SRC
4 cell surface receptor signaling pathway GO:0007166 9.79 EGFR ERBB2 MET
5 MAPK cascade GO:0000165 9.74 EGFR ERBB2 MET
6 protein autophosphorylation GO:0046777 9.72 EGFR ERBB2 SRC
7 epidermal growth factor receptor signaling pathway GO:0007173 9.64 EGFR SRC
8 myelination GO:0042552 9.63 ERBB2 KLK6
9 positive regulation of cell adhesion GO:0045785 9.63 ERBB2 SRC
10 cellular response to epidermal growth factor stimulus GO:0071364 9.62 EGFR ERBB2
11 liver regeneration GO:0097421 9.61 EGFR TYMS
12 cellular response to reactive oxygen species GO:0034614 9.6 EGFR SRC
13 peptidyl-tyrosine autophosphorylation GO:0038083 9.59 EGFR SRC
14 ERBB2 signaling pathway GO:0038128 9.58 EGFR ERBB2
15 regulation of cell motility GO:2000145 9.58 EGFR ERBB2
16 regulation of ERK1 and ERK2 cascade GO:0070372 9.56 EGFR ERBB2
17 positive regulation of MAP kinase activity GO:0043406 9.56 EGFR ERBB2 MST1R SRC
18 peptidyl-tyrosine phosphorylation GO:0018108 9.55 EGFR ERBB2 MET MST1R SRC
19 hepatocyte growth factor receptor signaling pathway GO:0048012 9.54 MET MST1R
20 cell differentiation GO:0030154 9.52 EGFR SRC
21 entry of bacterium into host cell GO:0035635 9.49 MET SRC
22 negative regulation of ERBB signaling pathway GO:1901185 9.48 EGFR ERBB2
23 negative regulation of apoptotic process GO:0043066 9.4 EGFR SRC
24 positive regulation of protein kinase B signaling GO:0051897 9.35 EGFR ERBB2 MET MST1R SRC
25 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.32 EGFR SRC
26 positive regulation of MAPK cascade GO:0043410 9.07 ERBB2
27 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.02 EGFR ERBB2 MET MST1R SRC
28 signal transduction GO:0007165 10.02 EGFR ERBB2 MET MST1R SRC

Molecular functions related to Gastroesophageal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.88 EGFR ERBB2 MET MST1R SRC
2 kinase activity GO:0016301 9.77 EGFR ERBB2 MET MST1R SRC
3 nucleotide binding GO:0000166 9.76 EGFR ERBB2 MET TYMS
4 enzyme binding GO:0019899 9.73 EGFR GSTM1 MST1R SRC
5 transferase activity GO:0016740 9.7 EGFR ERBB2 GSTM1 MET MST1R SRC
6 protein kinase activity GO:0004672 9.65 EGFR ERBB2 MET MST1R SRC
7 protein phosphatase binding GO:0019903 9.58 EGFR ERBB2 MET
8 Wnt-protein binding GO:0017147 9.49 MET MST1R
9 transmembrane signaling receptor activity GO:0004888 9.32 EGFR ERBB2
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.26 EGFR ERBB2 MET MST1R
11 protein tyrosine kinase activity GO:0004713 9.02 EGFR ERBB2 MET MST1R SRC

Sources for Gastroesophageal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....